osimertinib
astrazeneca
['osimertinib']
 if equitable access to osimertinib during relapse for all patients in control arm, i have doubts about os benefits #asco23 
Medical Oncology focused on Breast and Lung Cancer at https://t.co/hCfxKt8kbP and https://t.co/YeizvuTGR3 Opinions are my own. 🔁not